Uncategorized
Ocular Therapeutix™ Outlines Development Strategy for Its Sustained Release Intravitreal Depots to Address Serious Retinal Diseases
BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today provided an update on the Company’s development strategy for its sustained release intravitreal depot technology for the treatment of serious retinal diseases. The Company is currently developing proprietary sustained-release hydrogel-based drug delivery depots for intravitreal
